Asymptomatic chronic partial obstruction of a normal ureter following dextranomer/hyaluronic acid copolymer (Deflux®) injection for grade I vesicoureteral reflux.
Endoscopic management of vesicoureteral reflux with dextranomer/hyaluronic copolymer (Deflux(®), Oceana Therapeutics, Inc., Edison, NJ, USA) has gained widespread acceptance with increasing success rates and minimal morbidity. Formation of a pseudocapsule and calcification are known histologic changes at the injection site. Postoperative ureteral obstruction has been reported in cases of severe voiding dysfunction, neurogenic bladder and abnormal ureteral anatomy. We present a case of chronic asymptomatic obstruction in a normal ureter following injection of 0.7 ml Deflux.
Department of Urology, University of Iowa, Iowa City, IA 52242-1089, USA.
Angela M
AM
Arlen
Brittany L
BL
Pakalniskis
Christopher S
CS
Cooper
D002908:Chronic Disease; D003911:Dextrans / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000009:adverse effects*; D007223:Infant; D007267:Injections; D019736:Prostheses and Implants; D011475:Prosthesis Failure; D013997:Time Factors; D014513:Ureter; D014517:Ureteral Obstruction / Q000175:diagnosis / Q000209:etiology* / Q000601:surgery; D013520:Urologic Surgical Procedures / Q000379:methods; D014718:Vesico-Ureteral Reflux / Q000628:therapy*
D003911:Dextrans; C094535:deflux; D006820:Hyaluronic Acid